biostudies-literatureSharmin SNational Health and Medical Research CouncilUniversity of Tasmania2321-2334https://www.ebi.ac.uk/biostudies/studies/S-EPMC9539581biostudies-literatureUnknown29(8)<h4>Background and purpose</h4>The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of resulting in sustained long-term disability worsening.<h4>Methods</h4>In total, 14,802 6-month confirmed disability progression events were identified in 8741 patients from the global MSBase registry. For each 6-month confirmed progression event (13,321 in the development and 1481 in the validation cohort), a sustained progression score was calculated based on the demographic and clinical characteristics at the time of progression that were predicEuropean journal of neurologyConfirmed disability progression as a marker of permanent disability in multiple sclerosis.PMC9539581112918911577171140766BT000001Alroughani RSlee MSinghal BKalincik TKermode ABovis FSola PVucic SSidhom YYamout BShaygannejad VHughes SMalpas Cvan der Walt ALugaresi ATaylor BVan Wijmeersch BSirbu CAMcCombe PHavrdova EKOzakbas SIuliano Gde Gans KBuzzard KFerraro DDominguez JASaladino MLKappos LMacdonell RRozsa CDuquette PSolaro CGrammond PShuey NPrat ATurkoglu RBoz Cvan Pesch VShaw CHorakova DCsepany TCristiano ETrojano MBergamaschi RCartechini ESormani MPGouider RGerlach OLechner-Scott JSimo MOnofrj MSpitaleri DBarnett MIzquierdo GEichau SGirard MAl-Harbi TGrand'Maison FButler ESkibina OPrevost JCastillo-Trivino TGray OGranella FButzkueven HSoysal ATerzi MPetersen TSanchez-Menoyo JLSempere APFragoso YAmpapa RHodgkinson SMoore FSharmin SfalseConfirmed disability progression as a marker of permanent disability in multiple sclerosis.<h4>Background and purpose</h4>The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of resulting in sustained long-term disability worsening.<h4>Methods</h4>In total, 14,802 6-month confirmed disability progression events were identified in 8741 patients from the global MSBase registry. For each 6-month confirmed progression event (13,321 in the development and 1481 in the validation cohort), a sustained progression score was calculated based on the demographic and clinical characteristics at the time of progression that were predic2022-01-01T00:00:00Z2022 Aug2026-03-31T11:54:47.388Z2025-04-04T20:04:02.405ZS-EPMC95395813558293810.1111/ene.15406